Organovo Holdings, Inc. (ONVO) Cash per Single Share

Lack of profitability and R&D expenses are creating pressure, which is reflected in the fluctuations of cash per share, where the current level equals 0.67. Meanwhile, Organovo Holdings, Inc. is recognized as a leader in liver metabolism modeling. 3D bioprinting tissue technologies for pharma behemoths ensure business resilience, confirming its status as a pioneer in creating living structures for medicine.
Comprehensive metric breakdowns and analytics for organovo.com (ONVO)

Organovo Holdings, Inc. (ONVO) is implementing capital-intensive developments in 3D bioprinting of tissues for liver therapy. These R&D expenses directly impact the calculation of liquid assets per common share. This metric measures the available cash reserve, determining the business's ability to fund expansion without external borrowing. A decrease in cash per share may indicate active investment in engineering. The trend in this cash per share metric helps assess the risk of capital depletion.